For more than 40 years, aspirin has been a key therapy for patients with cardiovascular disease used to reduce the risk of a future cardiovascular event such as a heart attack or stroke. For the millions of Americans with heart disease, doctors variably recommend high-dose (325 mg) or low-dose (81 mg) aspirin with no clear preference for either dose. Furthermore, among the current American College of Cardiology (ACC)/ American Heart Association (AHA) Guideline Recommendations for cardiovascular conditions such as acute myocardial infarction, stable ischemic heart disease, and percutaneous coronary intervention, there is no consensus for a preferred dose of aspirin likely due to the relative lack of data from randomized trials regarding the optimal dose of aspirin for balancing the benefits vs. the known risks of bleeding and gastrointestinal intolerance seen with aspirin.
Results from the ADAPTABLE trial will provide the high-quality data needed to inform future treatment decisions for the best dose of aspirin for patients with cardiovascular disease and to clarify practice guideline recommendations regarding aspirin dose. Watch these videos featuring Former Food and Drug Association (FDA) Commissioner, Dr. Robert Califf, and cardiologists Drs. Daniel Munoz and Robert Harrington, who will provide their perspective on the importance of determining the optimal dose of aspirin for cardiovascular disease.